UnitedHealth CEO: Unknowns of Biogen Alzheimer’s drug mean insurer won’t yet cover it
(By Nick Moran for Becker’s Hospital Review) UnitedHealth Group CEO Andrew Witty said the payer needs to see more data on
Read More(By Nick Moran for Becker’s Hospital Review) UnitedHealth Group CEO Andrew Witty said the payer needs to see more data on
Read More(By Rachel Dolan and Elizabeth Williams for Kaiser Family Foundation published July 13, 2021) The recent approval of Aduhelm (aducanumab),
Read More(By Nick Moran for Becker’s Hospital Review) The Alzheimer’s Association joins insurers as the latest to call for CMS to
Read More(By Elisabeth Rosenthal for Kaiser Health News) The Food and Drug Administration’s approval in June of a drug purporting to
Read More(By Judith Graham for Kaiser Health News) As physicians and health policy experts debate the merits of Aduhelm, the first
Read More(By Judith Graham for Kaiser Health News) If you could invest $56 billion each year in improving health care for
Read More(By Lauren Jensik for Becker’s Hospital Review) Medicare members could face barriers to accessing Biogen’s new Alzheimer’s drug, Aduhelm, due to
Read More(By Rachel Cohrs and J. Emory Parker for STAT) The Food and Drug Administration’s decision to grant wide-ranging approval to
Read More(By Nick Moran for Becker’s Hospital Review) Point32Health may not cover Biogen’s new Alzheimer’s treatment, Aduhelm, for its commercial members unless
Read More(By Megan Molteni for STAT) For families and physicians grappling with the historic approval this month of the controversial Alzheimer’s
Read More